ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Folic acid: Pediatric drug information

Folic acid: Pediatric drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Folic acid: Drug information" and "Folic acid: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • FA-8 [OTC];
  • True Folic Acid [OTC]
Brand Names: Canada
  • JAMP-Folic Acid;
  • SANDOZ Folic Acid
Therapeutic Category
  • Nutritional Supplement;
  • Vitamin, Water Soluble
Dosing: Neonatal

Note: Doses are expressed as folic acid, unless otherwise noted. For oral dosing, folic acid 1 mg = dietary folate equivalent (DFE) 1.67 mg (when taken with food) or DFE 2 mg (if taken on an empty stomach). Compounded oral suspensions may be available in multiple concentrations; precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg amount.

Adequate intake (AI): Note: Recommended intake from dietary sources (eg, breast milk, formula); dose expressed as dietary folate equivalents (Ref). Neonates: 65 mcg DFE/day (Ref).

Parenteral nutrition, maintenance requirement of folic acid

Parenteral nutrition, maintenance requirement of folic acid (Ref): Premature and full-term neonates: IV: 56 mcg/kg/day.

Dosing: Pediatric

Note: Doses are expressed as folic acid. For oral dosing, folic acid 1 mg = dietary folate equivalent (DFE) 1.67 mg (when taken with food) or DFE 2 mg (if taken on an empty stomach). Compounded oral suspensions may be available in multiple concentrations; precautions should be taken to verify and avoid confusion between the different concentrations; dose should be clearly presented as mg amount.

Anemia, treatment

Anemia (folic acid deficiency), treatment:

Note: Parenteral route may be necessary for severe disease or if gastrointestinal absorption is impaired.

Initial: Infants, Children, and Adolescents: Oral, IM, IV, SUBQ: 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response (Ref).

Maintenance: Note: A multivitamin containing 0.2 mg folic acid may be adequate for maintenance (Ref).

Infants: Oral, IM, IV, SUBQ: 0.1 mg/day.

Children <4 years: Oral, IM, IV, SUBQ: 0.1 to 0.3 mg/day.

Children ≥4 years and Adolescents: Oral, IM, IV, SUBQ: 0.1 to 0.4 mg/day.

Parenteral nutrition, maintenance requirement of folic acid

Parenteral nutrition, maintenance requirement of folic acid (Ref):

Infants: IV: 56 mcg/kg/day.

Children and Adolescents: IV: 140 mcg/day.

Gingival hyperplasia due to phenytoin, prevention

Gingival hyperplasia due to phenytoin, prevention: Limited data available: Children ≥6 years and Adolescents: Oral: 0.5 mg/day; dosing based on results from a double-blind, randomized, placebo-controlled trial of 120 pediatric patients (treatment arm, n=62; age range: 6 to 15 years) who were started on phenytoin therapy; folate treatment resulted in lower rate of hyperplasia (treatment arm: 21% vs placebo: 88%); severity was also lower in treated patients compared to placebo (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Adult

(For additional information see "Folic acid: Drug information")

Note: Doses are expressed as folic acid. For oral dosing, folic acid 1 mg = dietary folate equivalent (DFE) 1.67 mg (if administered with food) or DFE 2 mg (if taken on an empty stomach).

Alcohol withdrawal syndrome

Alcohol withdrawal syndrome (adjunctive agent) (off-label use): Oral, IV: 400 mcg to 1 mg daily until no longer at risk (Ref). Note: IV route is preferred for patients with suspected or confirmed Wernicke encephalopathy who are critically ill (Ref).

Megaloblastic and macrocytic anemias due to folate deficiency

Megaloblastic and macrocytic anemias due to folate deficiency:

Oral: 1 to 5 mg once daily (Ref); doses up to 15 mg once daily have also been recommended (Ref).

Manufacturer's labeling: Dosing in the prescribing information may not reflect current clinical practice. Oral, IM, IV, SUBQ: Initial: 0.4 to 1 mg/day.

Maintenance dose: 0.4 mg/day.

Pregnant and lactating women: Maintenance dose: 0.8 mg/day.

Methanol toxicity

Methanol toxicity (adjunctive cofactor therapy; alternative agent) (off-label use): Therapy should continue until methanol and formic acid have been completely eliminated (Ref). Cofactors are adjunctive to antidotal therapy and should never be used alone.

IV: 50 to 70 mg every 4 hours (Ref).

Oral: 50 mg every 3 to 4 hours (Ref).

Prevention of neural tube defects

Prevention of neural tube defects (off-label use):

Females of childbearing potential: Oral: 0.4 mg/day (Ref) or 0.4 to 0.8 mg/day (Ref). Supplementation should start ≥1 month prior to pregnancy and continue through 12 weeks gestation (Ref).

Females at high risk, who have had a previous pregnancy with a neural tube defect, or with family history of neural tube defects: Oral: 4 mg/day. Supplementation should start ≥3 months prior to pregnancy and continue through 12 weeks gestation (Ref).

Supplementation to reduce toxicity associated with antifolate chemotherapy

Supplementation to reduce toxicity associated with antifolate chemotherapy (off-label use):

To reduce toxicity associated with pemetrexed: Oral: Administer folic acid 0.35 to 1 mg once daily, beginning 1 to 3 weeks prior to pemetrexed treatment initiation; continue for 3 weeks after the last pemetrexed dose; administer with intramuscular cyanocobalamin supplementation (Ref).

To reduce toxicity associated with pralatrexate: Oral: Administer folic acid 1 to 1.25 mg once daily (Ref), beginning 10 days prior to pralatrexate treatment initiation; continue for 30 days after the last pralatrexate dose; administer with intramuscular cyanocobalamin supplementation.

Supplementation to reduce toxicity associated with chronic methotrexate therapy for nononcology uses

Supplementation to reduce toxicity associated with chronic methotrexate therapy for nononcology uses (off-label use):

Note: For use during chronic methotrexate therapy for nononcology indications to reduce the risk of adverse effects (eg, nausea, vomiting, diarrhea, hepatotoxicity) (Ref). Do not use in patients receiving methotrexate for oncology indications due to potential for reduced methotrexate efficacy (Ref).

Oral: Initial: 1 mg once daily administered 5 to 7 days each week (Ref). May gradually increase dose if needed based on response; may also consider doubling the folic acid dose if the methotrexate dosage is increased to ≥15 mg/week (Ref). Usual dose range: 1 to 5 mg/day on 5 to 7 days each week (5 to 27.5 mg/week) (Ref). Note: The optimal dosing strategy has not been defined; increasing the dosage above 10 mg/week may not be associated with additional benefit (Ref). Leucovorin may be considered in patients who do not respond to folic acid (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.

Cardiovascular: Flushing (slight)

Central nervous system: Malaise (general)

Dermatologic: Erythema, pruritus, skin rash

Hypersensitivity: Hypersensitivity reaction

Respiratory: Bronchospasm

Contraindications

IV: There are no contraindications listed within the manufacturer's labeling.

Oral: Hypersensitivity to folic acid or any component of the formulation.

Warnings/Precautions

Disease-related concerns:

• Anemia: Monotherapy: Not appropriate for monotherapy with pernicious, aplastic, or normocytic anemias when anemia is present with vitamin B12 deficiency.

• Pernicious anemia: Doses >0.1 mg/day may obscure pernicious anemia with continuing irreversible nerve damage progression.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer’s labeling.

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997], CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

Other warnings/precautions:

• Methanol toxicity: Folic acid should be used only if leucovorin is unavailable. Leucovorin is the reduced form of folic acid; leucovorin is rapidly converted to tetrahydrofolic acid derivatives which are the storage forms of folate in the body. Because leucovorin does not require metabolic reduction, it is the preferred form of folate in the treatment of methanol toxicity (Barceloux 2002).

• Resistance to treatment: May occur with depressed hematopoiesis, alcoholism, and deficiencies of other vitamins.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral [preservative free]:

FA-8: 0.8 mg [dye free, sugar free, yeast free]

Generic: 5 mg, 20 mg

Solution, Injection, as sodium folate:

Generic: 5 mg/mL (10 mL)

Tablet, Oral:

True Folic Acid: 400 mcg, 1 mg

Generic: 400 mcg, 800 mcg, 1 mg

Tablet, Oral [preservative free]:

Generic: 800 mcg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (FA-8 Oral)

0.8 mg (per each): $0.04

Capsules (Folic Acid Oral)

5 mg (per each): $0.07

20 mg (per each): $0.08

Solution (Folic Acid Injection)

5 mg/mL (per mL): $4.38 - $6.73

Tablets (Folic Acid Oral)

1 mg (per each): $0.06 - $0.37

400 mcg (per each): $0.02

800 mcg (per each): $0.03 - $0.05

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Injection, as sodium folate:

Generic: 5 mg/mL (10 mL)

Tablet, Oral:

Generic: 5 mg, 25 mg [DSC]

Extemporaneous Preparations

1 mg/mL Oral Solution

A 1 mg/mL folic acid oral solution may be made with tablets. Heat 90 mL of purified water almost to boiling. Dissolve parabens (methylparaben 200 mg and propylparaben 20 mg) in the heated water; cool to room temperature. Crush one-hundred 1 mg tablets, then dissolve folic acid in the solution. Adjust pH to 8-8.5 with sodium hydroxide 10%; add sufficient quantity of purified water to make 100 mL; mix well. Stable for 30 days at room temperature (Allen 2007).

Allen LV Jr, "Folic Acid 1-mg/mL Oral Liquid," Int J Pharm Compound, 2007, 11(3):244.

0.05 mg/mL Oral Solution

A 0.05 mg/mL folic acid oral solution may be prepared using the injectable formulation (5 mg/mL). Mix 1 mL of injectable folic acid with 90 mL of purified water. Adjust pH to 8-8.5 with sodium hydroxide 10%; add sufficient quantity of purified water to make 100 mL; mix well. Stable for 30 days at room temperature (Nahata 2004).

Nahata MC, Pai VB, and Hipple TF, Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.
Additional Information

Dietary folate equivalents (DFE) is used to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement (IOM 1998; NIH 2021):

1 mcg DFE = 0.6 mcg folic acid from fortified food or as a supplement taken with meals

1 mcg DFE = 0.5 mcg of a supplement taken on an empty stomach

Administration: Pediatric

Oral (preferred): May be administered without regard to meals

Parenteral:

IM, SubQ: May administer undiluted deep IM or SubQ

IV: May administer doses ≤5 mg undiluted over ≥1 minute or may further dilute and infuse over 30 minutes. May also be given as an infusion when added to IV maintenance solutions.

Administration: Adult

Oral preferred, but may also be administered by deep IM, SUBQ, or IV injection.

IV administration: May administer ≤5 mg dose undiluted over ≥1 minute or may further dilute and infuse over 30 minutes. May also be added to IV maintenance solutions and given as an infusion.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); protect injection from light.

Use

Treatment of megaloblastic and macrocytic anemias due to folate deficiency (FDA approved in all ages); has also been used as a dietary supplement to prevent neural tube defects and prevention of gingival hyperplasia due to phenytoin

Medication Safety Issues
Sound-alike/look-alike issues:

Folic acid may be confused with folinic acid (leucovorin calcium)

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Fluorouracil Products: Folic Acid may enhance the adverse/toxic effect of Fluorouracil Products. Risk C: Monitor therapy

Fosphenytoin-Phenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin-Phenytoin. Risk C: Monitor therapy

Green Tea: May decrease the serum concentration of Folic Acid. Risk C: Monitor therapy

Pafolacianine: Folic Acid may diminish the diagnostic effect of Pafolacianine. Risk X: Avoid combination

PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital. Risk C: Monitor therapy

Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). Risk C: Monitor therapy

Pyrimethamine: Folic Acid may diminish the therapeutic effect of Pyrimethamine. Management: Folic acid doses greater than 2.5 mg per day should be avoided due to the potential for sulfadoxine/pyrimethamine treatment failure. Consider limiting folic acid use to no more than 0.4 mg per day for women of child-bearing age. Risk D: Consider therapy modification

Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed. Risk X: Avoid combination

Sulfadoxine: Folic Acid may diminish the therapeutic effect of Sulfadoxine. Management: Folic acid doses greater than 2.5 mg per day should be avoided due to the potential for sulfadoxine/pyrimethamine treatment failure. Consider limiting folic acid use to no more than 0.4 mg per day for women of child-bearing age. Risk D: Consider therapy modification

SulfaSALAzine: May decrease the serum concentration of Folic Acid. Risk C: Monitor therapy

Dietary Considerations

As of January 1998, the FDA has required manufacturers of enriched flour, bread, corn meal, pasta, rice, and other grain products to add folic acid to their products. The intent is to help decrease the risk of neural tube defects by increasing folic acid intake. Other foods which contain folic acid include dark green leafy vegetables, citrus fruits and juices, and lentils.

Dietary adequate intake (AI) (IOM 1998): Expressed as dietary folate equivalents:

1 to 6 months: 65 mcg/day

7 to 12 months: 80 mcg/day

Dietary recommended daily allowance (RDA) (IOM 1998): Expressed as dietary folate equivalents:

1 to 3 years: 150 mcg/day

4 to 8 years: 200 mcg/day

9 to 13 years: 300 mcg/day

>13 years: 400 mcg/day

Pregnancy: 600 mcg/day

Lactation: 500 mcg/day

Reproductive Considerations

Folate supplementation during the periconceptual period decreases the risk of neural tube defects. All females planning a pregnancy or who may potentially become pregnant should begin folic acid supplementation prior to conception. Higher doses are required in females at high risk of neural tube defects (ACOG 187 2017; USPSTF [Bibbins-Domingo 2017]).

Pregnancy Considerations

Water soluble vitamins cross the placenta (IOM 1998).

Folate requirements increase during pregnancy (IOM 1998). Folate supplementation during the periconceptual period decreases the risk of neural tube defects. Higher doses are required in females at high risk of neural tube defects (ACOG 187 2017; USPSTF [Bibbins-Domingo 2017]). Folic acid is also indicated for the treatment of anemias due to folate deficiency in pregnant women.

Monitoring Parameters

CBC with differential

Reference Range

Note: Reference ranges may vary depending on the laboratory.

Serum folate (Kliegman 2020):

Normal range: 5 to 20 ng/mL (SI: 11.3 to 45.3 nmol/L)

Folate deficiency: <3 ng/mL (SI: <6.8 nmol/L)

Mechanism of Action

Folic acid is necessary for formation of a number of coenzymes in many metabolic systems, particularly for purine and pyrimidine synthesis; required for nucleoprotein synthesis and maintenance in erythropoiesis; stimulates WBC and platelet production in folate deficiency anemia.

In patients exposed to methanol, the toxic metabolite formic acid is bound to tetrahydrofolate and metabolized to carbon dioxide and water by 10-formyltetrahydrofolate dehydrogenase. Hypothetically, administration of folic acid enhances the metabolism of formic acid to nontoxic metabolites (Barceloux 2002).

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Proximal part of small intestine

Metabolism: Hepatic

Bioavailability: Oral: Folic acid supplement: ~100%; In presence of food: 85%; Dietary folate: 50% (IOM 1998)

Time to peak: Oral: 1 hour

Excretion: Urine

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Folic Acid Generic | Folicare | Folicid | Folicum | Folitab | Folvit | Folvyte | Folwin | Infacare | Mithra folic | Neofolic | Preconceive | Sunvit folic acid;
  • (AR) Argentina: Acido folico | Acido folico hw | Acido folico omega | Acido folico richmond | Acido folico vannier | Acifol | Anemidox Folico | Anfolic | Arisfolic | Bernafolic | Coflic | Conacid | Egestan Folico | Folaport | Foliagen | Folimax | Folinemic | Nexovital Folico | Ronfolic | Sojar Folico | Suprafol | Tanvimil folico;
  • (AT) Austria: Acidum folicum leciva | Folsaeure-Solvay | Folsan | Gerofol | Sodiofolin;
  • (AU) Australia: Cenovis folic acid | Folate | Folicid | Foltabs | Megafol | Microgenics folic acid | Soul pattinson folic acid;
  • (BD) Bangladesh: Folac | Folate | Folison | Folus | Prefol;
  • (BE) Belgium: Folavit | Foliphar;
  • (BF) Burkina Faso: Acfol | Acide folique | Acide folique tm;
  • (BG) Bulgaria: Acidum folicum | Neopholic | Retafol;
  • (BR) Brazil: 4g folic | Acfol | Acido folico | Acido folico b9 | Acifolico | Afolic | Afopic | Befolik | Bravitan | Endofolin | Femme folico | Fluence | Folacin | Folantine | Folifase | Folifolin | Folinium | Folital | Folitrat | Folonin | Gestancare | Hipofol | Mater folic | Materfolic | Metilfolin | Neo folico | Nesh folico | Pratifolin | Pre folic | Regenesis folato | Sidney oliveira acido folico | Vitafol | Vitamina b9;
  • (CH) Switzerland: Acidum Folicum Haenseler | Acidum folicum streuli | Andreafol | Fertifol | Folsaeure burgerstein | Folvite | Metofol;
  • (CI) Côte d'Ivoire: Acide folique | Folicil;
  • (CL) Chile: Folacid | Folifemin | Folisanin | Miliser;
  • (CN) China: Du tai | Mei tian fu | Si li an;
  • (CO) Colombia: Acepilan | Acido folico | Folib 9 | Folic prevent | Solgar folate;
  • (DE) Germany: Alnavit Folsaeure | Aov folsaeure | Aponeo folsaeure | Aportha folsaeure | Apovital folsaeure | Cellufine folsaeure | Dreisafol | EuRho Vital folsaeure | Femisanit | Floradix folsaeure | Florafol Folsaeure | Fol | Fol asmedic | Fol-5 | Folacin Solgar | Folarell | Folcur | Folgamma mono | Folica | Folisyx Folsaeure | Folsaeure | Folsaeure 800 | Folsaeure compact | Folsaeure CT | Folsaeure Hexal | Folsaeure Lyssia | Folsaeure Sandoz | Folsaeure stada | Folsan | Folsaure ratiopharm | Folsaure sanavita | Folsaure vitbalans | Folverlan | Gravi fol | Innovafolat | Naturafit folat 800 aktiviert | Naturavegan folsaeure | Nobilin Folsaeure | Oekothek folsaeure aktiv | Omnivit Folsaeure | Oncofolic | Phytholistic folsaeure | Rubiefol | Tasnim folsaeure | Vitafol | Vitamin b9 | Weno Fol;
  • (DK) Denmark: Apovit folsyre | Apovit folsyre staerk | Folinsyre sad | Nycoplus folsyre;
  • (DO) Dominican Republic: Acido folico | Acido folico alfa | Acifol | Afolin | Cefovid | Egestan Folico | Falcifor | Folicil | FoliFran | Folimen | Foliner | Folitab | Folvite | Inafol | Suvit;
  • (EC) Ecuador: Acido folico | Ecufol | Nature's bounty folic acid;
  • (EE) Estonia: A. foolhape | Acidum folicum | Acidum folicum hasco | Acifolic | Folic acid vitabalans | Folverlan | Foolhape | Iconfit folic acid | Nogel folaat quatrefolic | Olimp foolhape;
  • (EG) Egypt: Folicap | Folicurex | Foliraq | Sansofolic;
  • (ES) Spain: Acfol | Acido folico aspol | Bialfoli | Folic acid qualigen | Zolico;
  • (FI) Finland: Folic acid vitabalans | Foliver | Folvite;
  • (FR) France: Acide folique | Acide folique arrow | Acide folique mylan | Fertifol | Prefolic | Speciafoldine | Spinafol;
  • (GB) United Kingdom: C&g folic acid | Folic acid almus | Folic acid arrow | Folic acid astec | Folic acid cox | Folic acid dc | Folic acid kent | Folic acid zanza | St Georges | Valupak Folic Acid | Vitafol;
  • (GR) Greece: Fanolit | Filicine;
  • (HK) Hong Kong: Apo-Folic Acid | Blackmores folate | Filicin | Foliamin | Folicil;
  • (HR) Croatia: Folacin | Folbella | Twinlab folna kiselina;
  • (HU) Hungary: Folsav | Folsav vitabalans | Huma-folacid;
  • (ID) Indonesia: Acidum folicum | Afolat | Anelat | Anemolat | Fionat | Folac | Folacom | Folamef | Folaris | Folas | Folavicap | Folavit | Folaxin | Nufolic | Nuvita nutri folic | Profolat | Vitafol;
  • (IE) Ireland: Cardio guard | Clonfolic | Sona folic acid;
  • (IL) Israel: Folic;
  • (IN) India: Afol | Agifol | Alfol | Anaefol | B 9 | Biolic | Defol | Eldefol | Emfol | Emfolic | F-5 | Fa | Fa od | Facitab | Fevifol | Fh-12 | Fol | Fol B | Fol-v | Folacin | Folax | Folcid | Folcin | Foldivit | Folera | Folet | Folfine | Folfit | Foli plus | Folic | Folica | Folicam | Folicare | Folicid | Foliden | Folifit | Folik | Folikem | Folinal | Folinol | Folitab | Folitas | Folite | Folium ds | Foliwel | Folmet | Folnate | Folneu | Folrite | Folson | Foltop | Folvite | Goodvit | Ingafol | Krisfol | Mega v | Momfol | Olic | Pravy | Qfol | Ranfcid | Rufol | Sysfol | Tetrafol | U fol | Ultrafolin | Uni fol | Vifol | Vitafol | Vitalin | Vitriv f | Zyfolic;
  • (IQ) Iraq: Acid folic | Folic | Folic awa | Furafolic;
  • (IT) Italy: Acido folico | Acido folico aristo | Acido folico doc generici | Acido folico eg | Balfolic | Biofolic | Fertifol | Folatex | Folicalgyn | Folicom | Folidex | Folifem | Folifill | Folina | Furoic | Monofolic | Prefolic;
  • (JO) Jordan: Appeton essentials folic acid | Folate | Folicel | Folix | Folvyte | Lyane Folic Acid | Pregnio fol | Valupak Folic Acid | Vifolin | Vitafol;
  • (JP) Japan: Foliamin | Foliamin Nichiyaku | Foliamin takeda | Folic acid aventis;
  • (KE) Kenya: Pinfol;
  • (KR) Korea, Republic of: Folcid | Folda | Folen | Folga | Folin | Folmam | Folone | Folredi | Gcp folic acid | Ildong folic acid | Moms folic | Onefoll | Pmg folic acid | Sinil folic acid;
  • (KW) Kuwait: Folavit | Folicare | Folicum | Folitab | Nature Made Folic Acid;
  • (LB) Lebanon: Davinci folic acid | Folac | Folicil | Folix;
  • (LT) Lithuania: Acidum folicum | Apo folic | Bioaktyvi folio rugstis | Folic rugstis | Folica | Folio rugstis | Folsan | Folverlan | Nutrisave folic acid | Tifol | Vitaday folio rugstis;
  • (LU) Luxembourg: Folavit | Speciafoldine;
  • (LV) Latvia: A folijskabe | Acidum folicum | Benu folic acid | Folic acid vitabalans | Folica | Folijskabe | Folskabe | Folverlan | Live well folic acid | Olvel folic acid | Tifol;
  • (MA) Morocco: Acfol;
  • (MX) Mexico: A.F Valdecasas | A.f. valdecasas | Acido folico | Acido folico nucitec | Acido Folico Solara | Acido folico ultra | Af valdecasas | Cilocid | Envacal | Expledin | Folicid | Folitab | Folivital | Grufecopu | Mafolic | Materfol | Novafol | Prinac AC;
  • (MY) Malaysia: Apo folic | Appeton Folic Acid | Duafolic | Foliamin | Gnc folic acid;
  • (NG) Nigeria: Cinafolic | Galways folic acid | Gauze folic acid | Jopan folic acid;
  • (NL) Netherlands: Foliumzuur | Foliumzuur actavis | Foliumzuur Kring | San foliumzuur;
  • (NO) Norway: Folimet | Folsan | Folsyre | Folsyre naf | Folsyre orifarm | Nycoplus folsyre;
  • (NZ) New Zealand: Apo-Folic Acid | Blackmores folate daily | Folic acid mylan | Folic acid viatris | Pharmacycare folic acid | Solgar folacin;
  • (PE) Peru: Acido folico | Vitafolic;
  • (PH) Philippines: Aneftor | Aslic | Cefolic | Enhansid | Feri | Fetanium | Folac | Folacid | Foladin | Folart | Foleq | Foliage | Folic acid ritemed | Folicap | Folicare | Folicon | Folicron | Folid | Folidyn | Folimax | Folimed | Folinc | Folineed | Folisure | G fol | Infacare | Ingafol | Maxifol 5000 | Ob clear | Obsure | Polik | Prevena | Purifol | Sanoviz fa | United home natafol;
  • (PK) Pakistan: Cybela | Deefol | Folib | Folic | Foliday | Folitab | Follick | Fourfolic | Greenfolic | Nufol | Prefol | Ultrafol;
  • (PL) Poland: Acidum folicum | Acidum folicum richter | Acifolik | Folacid | Folifem | Folifort | Folik | Folimin | Folovit | Kwas foliowy;
  • (PR) Puerto Rico: Fa 8 | Folvite | L Methylfolate;
  • (PT) Portugal: Acfol | Acido folico | Acido folico farmoz | Acido folico generis | Balfolic | Ellyfol | Enser | Folicil | Folidex;
  • (PY) Paraguay: Acido folico catedral | Acido folico dutriec | Acido folico empa | Acido folico fapasa | Acido folico fda | Acido folico millet | Acifol | Benzal | Biovitan folic | Fridalit | Gnc folic acid | Imeglobin | Miliser | Tanvimil folico | Tonixan;
  • (QA) Qatar: Folicum | Folitab | HealthAid Folic Acid | Lexpec;
  • (RO) Romania: Acifol;
  • (RU) Russian Federation: 9 months folic acid | Acidum folicum | Folacin | Mamifol;
  • (SA) Saudi Arabia: Befolvit | Folicum | Folvyte;
  • (SE) Sweden: Folacin | Folsyra actavis | Folsyra eql pharma | Folsyra Evolan | Folsyra orifarm | Folsyra Pilum | Folsyra vitabalans | Folvidon;
  • (SI) Slovenia: Folacin | Folna kislina vitabalans | Tifol;
  • (SY) Syrian Arab Republic: Folmed;
  • (TH) Thailand: F Min | Foliamin | Folimed | Folivit;
  • (TN) Tunisia: Acide folique | Folicum;
  • (TR) Turkey: Bio Folic Acid | Ensa folic | Folate | Folbetake | Folbiol | Folfull | Folicus | Folik asit | Gnc folic acid | Mrb folik asit | Nutraxin vitals folic acid | Pregniofol | Valupak Folic Acid;
  • (TW) Taiwan: Folacin | Folate;
  • (UA) Ukraine: Acidum folicum | Folic acid astra | Tifol;
  • (UG) Uganda: Asflic | Foliben | Foliren | Folon;
  • (UY) Uruguay: Acido folico | Acifol | Acirufan | Evry | Foliacid | Hayfolic | Insugen F;
  • (VE) Venezuela, Bolivarian Republic of: Acido folico | Afoklin | Afopic | Cofacifol | Folac | Nonafol;
  • (VN) Viet Nam: Aginfolix;
  • (ZA) South Africa: Be-tabs folic acid | Clicks folic acid | Folacin | Folate | Gnc folic acid | Gulf folic acid | Quadfolic;
  • (ZM) Zambia: Ar fol | Be-tabs folic acid | Folicant | Folid
  1. Alimta (pemetrexed) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; June 2018.
  2. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 187: Neural Tube Defects. Obstet Gynecol. 2017;130(6):e279-e290. doi:10.1097/AOG.0000000000002412 [PubMed 29189693]
  3. American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. J Addict Med. 2020;14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668 [PubMed 32511109]
  4. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  5. Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.
  6. Arya R, Gulati S, Kabra M, et al. Folic Acid Supplementation Prevents Phenytoin-Induced Gingival Overgrowth in Children. Neurology. 2011;76(15):1338-1343. [PubMed 21482950]
  7. Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-446. [PubMed 12216995]
  8. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Folic acid supplementation for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(2):183-189. doi:10.1001/jama.2016.19438 [PubMed 28097362]
  9. Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1084. doi:10.1212/NXI.0000000000001084 [PubMed 34607912]
  10. Bronsky J, Campoy C, Braegger C; ESPGHAN/ESPEN/ESPR/CSPEN Working Group on Pediatric Parenteral Nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Vitamins. Clin Nutr. 2018;37(6, pt B):2366-2378. [PubMed 30100105]
  11. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  12. Cook K, Lyons WL. Chapter 80. Anemias. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach. I9th edition. McGraw-Hill; 2014.
  13. Department of Health and Human Services, Food and Drug Administration, Nutrition Labeling. Fed Regist. 1980;45:69043.
  14. Dhir V, Sandhu A, Kaur J, et al. Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015;17(1):156. doi:10.1186/s13075-015-0668-4 [PubMed 26063325]
  15. Flannery AH, Adkins DA, Cook AM. Unpeeling the evidence for the banana bag: evidence-based recommendations for the management of alcohol-associated vitamin and electrolyte deficiencies in the ICU. Crit Care Med. 2016;44(8):1545-1552. doi:10.1097/CCM.0000000000001659 [PubMed 27002274]
  16. Folic acid 1 mg tablets [prescribing information]. Ft. Lauderdale, FL: ECI Pharmaceuticals LLC; March 2021.
  17. Folic acid 400 mcg tablets [prescribing information]. Richmond, VA: Richmond Pharmaceuticals Inc; 2015.
  18. Folic acid injection, solution [prescribing information]. Big Flats, NY: XGen Pharmaceuticals DJB Inc; September 2020.
  19. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-939. doi:10.1002/acr.24596 [PubMed 34101387]
  20. Hoffbrand A. Megaloblastic Anemias. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine. 19th edition. McGraw-Hill; 2015.
  21. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  22. IOM (Institute of Medicine). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. National Academy Press; 1998.
  23. Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020.
  24. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484 [PubMed 31562236]
  25. Liu L, Liu S, Wang C, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol. 2019;25(5):197-202. doi:10.1097/RHU.0000000000000810 [PubMed 29975207]
  26. Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis-a review. Br J Clin Pharmacol. 2019;85(10):2228-2234. doi:10.1111/bcp.14057 [PubMed 31276602]
  27. McGrath ER, Doughty CT, Amato AA. Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics. 2018;15(4):976-994. doi:10.1007/s13311-018-00676-2 [PubMed 30341597]
  28. Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther. 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x [PubMed 34143362]
  29. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044 [PubMed 32119894]
  30. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(11):833-841. doi:10.7326/0003-4819-121-11-199412010-00002 [PubMed 7978695]
  31. National Institutes of Health (NIH). Folate: fact sheet for health professionals. Updated March 29, 2021. https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/. Last accessed April 22, 2021.
  32. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-1189. doi:10.1200/JCO.2010.29.9024 [PubMed 21245435]
  33. Osterloh JD, Pond SM, Grady S, and Becker CE. Serum folate concentrations in methanol intoxication as a criterion for hemodialysis. Ann Internal Med. 1986;104:200-203. [PubMed 3946945]
  34. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160(3):622-628. doi:10.1111/j.1365-2133.2008.08876.x [PubMed 18945303]
  35. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375 [PubMed 18506025]
  36. Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021;76(1):4-20. doi:0.1136/thoraxjnl-2019-214348 [PubMed 33268456]
  37. Trexall (methotrexate) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; April 2021.
  38. van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(6):658-665. doi:10.1093/rheumatology/41.6.658 [PubMed 12048292]
  39. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44(7):1515-1524. doi:10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7 [PubMed 11465701]
  40. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products. Nutr Clin Pract. 2012;27(4):440-491. [PubMed 22730042]
  41. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2664. doi:10.1200/JCO.2003.11.136 [PubMed 12860938]
  42. Zakharov S, Pelclova D, Navratil T, et al. Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak. Clin Toxicol. 2015;53(8):797-806. doi:10.3109/15563650.2015.1059946 [PubMed 26109326]
Topic 13322 Version 461.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟